Archives for October 25, 2018

WuXi, CANbridge establish first known partnership in China to tackle rare diseases: CEO

WuXi Biologics and CANbridge Pharmaceutical have entered into a long-term partnership to develop and commercialize a portfolio of biotherapeutics for rare diseases.

Update

Charles River teams with Distributed Bio to advance antibody discovery platform

Charles River and Distributed Bio are creating an integrated antibody discovery and development platform as part of an exclusive partnership.

Following ‘the three Rs’: SGS to provide in vitro technology services at Mississauga site

SGS announced it will provide new in vitro toxicology services at its Mississauga, Canada Laboratory following an investment in instruments and laboratory capabilities.

LabCorp expects continued growth from Covance, despite headwinds in 2019

LabCorp sees significant opportunity to grow its Covance Drug Development business in the face of a potentially challenging 2019 and is on track to deliver costs savings as part of its LaunchPad initiatives.

US FDA approves first enzyme-blocking antiviral in 20 years

The US FDA approved Xofluza for the treatment of acute uncomplicated influenza, the first antiviral flu treatment to be approved in almost 20 years.

Remediation activities at non-GMP compliant site ‘progressing well’, says Recipharm

An MHRA audit of Recipharm’s facility in Ashton-under-Lyne has revealed the CDMO was deficient in certain manufacturing procedures for potent products.